Paragangliomas of urinary bladder are extremely rare which usually present with characteristic clinical picture in about half of the cases. We report a case where the presentation was unusual, leading to initial misdiagnosis corrected on histological review.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
SRT3025-loaded cell membrane hybrid liposomes (3025@ML) enhanced anti-tumor activity of Oxaliplatin via inhibiting pyruvate kinase M2 and fatty acid synthase.
Lipids Health Dis
January 2025
Department of Urology, Henan Provincial People's Hospital, Zhengzhou University People's Hospital, Henan University People's Hospital, Zhengzhou, 450003, China.
Background: Bladder cancer is one of the most common malignancies of the urinary system. Despite significant advances in diagnosis and treatment, the compromised therapeutic effect of chemotherapeutic agents, such as Oxaliplatin (OXA), remains a major clinical challenge. Thus, a combination therapy is required to enhance the OXA's therapeutic effectiveness and improve patient outcomes.
View Article and Find Full Text PDFCystitis glandularis due to Escherichia coli infection in a diabetic Miniature Schnauzer: a case report.
BMC Vet Res
January 2025
Faculty of Veterinary Sciences, University of Buenos Aires, Buenos Aires, Argentina.
Background: Lower urinary tract disease is a common clinical condition in dogs, usually presenting with dysuria, pollakiuria and haematuria. Diabetes mellitus is a predisposing factor for urinary tract infection in both humans and dogs and does not necessarily present with clinical signs. In this case report, we describe for the first time a case of cystitis glandularis in a dog with diabetes mellitus, associated with Escherichia coli urinary tract infection.
View Article and Find Full Text PDFNon-thermal plasma as promising anti-cancer therapy against bladder cancer by inducing DNA damage and cell cycle arrest.
Sci Rep
January 2025
Amsterdam UMC, Location VUmc, Cancer Center Amsterdam, de Boelelaan 1117, 1018 HV, Amsterdam, The Netherlands.
Bladder cancer often recurs, necessitating innovative treatments to reduce recurrence. We investigated non-thermal plasma's potential as a novel anti-cancer therapy, focusing on plasma-activated solution (PAS), created by exposing saline to non-thermal plasma. Our study aims to elucidate the biological effects of PAS on bladder cancer cell lines in vitro, as well as the combination with mitomycin C (MMC), using clinically relevant settings.
View Article and Find Full Text PDFThe incidence and risk factor for febrile urinary tract infection after robot-assisted laparoscopic radical cystectomy in bladder cancer patients.
J Infect Chemother
January 2025
Department of Urology, Sapporo Medical University School of Medicine, Sapporo, Japan.
Introduction: Febrile urinary tract infections are major complications of radical cystectomy; however, their characteristics after robot-assisted radical cystectomy remain unclear. Thus, we investigated the rate, severity, pathogens, and risk factors of febrile urinary tract infections after robot-assisted radical cystectomy.
Patients And Methods: Patients who underwent robot-assisted radical cystectomy at three institutions between April 2018 and March 2022 were retrospectively analyzed.
Non-coding RNAs in urinary bladder cancer microenvironment: Diagnostic, therapeutic, and prognostic perspective.
Pathol Res Pract
January 2025
Department of Pathology, Faculty of Medicine, Suez University, Suez, Egypt.
Urinary bladder cancer (UBC) is the ninth most common cancer worldwide. Despite the reliance of UBC therapy on definite pathological grading and classifications, the clinical response among patients varies widely. The molecular basis of this type of cancer appeals to considerable research; hence, new diagnostic and therapeutic options are introduced.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!